ATE254450T1 - Aerosolzusammensetzungen - Google Patents

Aerosolzusammensetzungen

Info

Publication number
ATE254450T1
ATE254450T1 AT96931227T AT96931227T ATE254450T1 AT E254450 T1 ATE254450 T1 AT E254450T1 AT 96931227 T AT96931227 T AT 96931227T AT 96931227 T AT96931227 T AT 96931227T AT E254450 T1 ATE254450 T1 AT E254450T1
Authority
AT
Austria
Prior art keywords
liquefied hydrofluoroalkane
fatty acid
active ingredient
medium
chain fatty
Prior art date
Application number
AT96931227T
Other languages
English (en)
Inventor
Saburo Murata
Fumio Shimojo
Yuji Tokunaga
Takehisa Hata
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE254450T1 publication Critical patent/ATE254450T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96931227T 1995-09-19 1996-09-18 Aerosolzusammensetzungen ATE254450T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23934295 1995-09-19
PCT/JP1996/002670 WO1997010806A1 (en) 1995-09-19 1996-09-18 Aerosol compositions

Publications (1)

Publication Number Publication Date
ATE254450T1 true ATE254450T1 (de) 2003-12-15

Family

ID=17043318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931227T ATE254450T1 (de) 1995-09-19 1996-09-18 Aerosolzusammensetzungen

Country Status (15)

Country Link
US (2) US6361760B1 (de)
EP (1) EP0851753B1 (de)
JP (2) JP3266005B2 (de)
KR (1) KR100523754B1 (de)
CN (1) CN1137680C (de)
AT (1) ATE254450T1 (de)
AU (1) AU719613B2 (de)
CA (1) CA2232378C (de)
DE (1) DE69630798T2 (de)
DK (1) DK0851753T3 (de)
ES (1) ES2206590T3 (de)
PT (1) PT851753E (de)
TW (1) TW429153B (de)
WO (1) WO1997010806A1 (de)
ZA (1) ZA967887B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041191A1 (en) * 1997-03-14 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Aerosol preparation
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US20040230272A1 (en) * 2003-04-11 2004-11-18 Cates Adam W. Subcutaneous lead with temporary pharmacological agents
MXPA05013324A (es) * 2003-06-10 2006-03-09 Astellas Pharma Inc Preparacion de aerosol comprendiendo un anexo que incluye una composicion de aerosol conteniendo compuesto macrolido.
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
KR20060124610A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP2007516951A (ja) * 2003-12-30 2007-06-28 アステラス製薬株式会社 気道閉塞症の治療または予防のためのマクロライドの使用
ZA200704889B (en) * 2004-11-23 2008-09-25 Celgene Corp JNK inhibitors for treatment of CNS injury
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
KR20110096538A (ko) * 2008-11-04 2011-08-30 씨아이피엘에이 엘티디. 약제학적 에어로졸 조성물
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (de) 2009-10-09 2019-02-27 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
US9321999B2 (en) 2009-11-19 2016-04-26 Solis Biodyne Oü Compositions for increasing polypeptide stability and activity, and related methods
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
DK0406791T3 (da) 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
PH31204A (en) 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
WO1992008474A2 (en) 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
US5601844A (en) 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5681501A (en) * 1995-10-11 1997-10-28 E. I. Du Pont De Nemours And Company Compositions including a hydrofluoropropane
WO1998041191A1 (en) * 1997-03-14 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Aerosol preparation
EP0978288A4 (de) 1997-04-11 2006-07-12 Astellas Pharma Inc Medizinische zusammensetzung

Also Published As

Publication number Publication date
TW429153B (en) 2001-04-11
KR19990044656A (ko) 1999-06-25
ES2206590T3 (es) 2004-05-16
CA2232378A1 (en) 1997-03-27
PT851753E (pt) 2004-04-30
CA2232378C (en) 2009-04-14
DE69630798T2 (de) 2004-09-23
ZA967887B (en) 1997-04-07
US20020061906A1 (en) 2002-05-23
AU719613B2 (en) 2000-05-11
JP2000505050A (ja) 2000-04-25
EP0851753A1 (de) 1998-07-08
DK0851753T3 (da) 2004-03-15
AU6999896A (en) 1997-04-09
KR100523754B1 (ko) 2007-06-04
JP3266005B2 (ja) 2002-03-18
HK1017845A1 (en) 1999-12-03
JP3362394B2 (ja) 2003-01-07
CN1137680C (zh) 2004-02-11
CN1201384A (zh) 1998-12-09
JPH09143054A (ja) 1997-06-03
EP0851753B1 (de) 2003-11-19
DE69630798D1 (de) 2003-12-24
US6361760B1 (en) 2002-03-26
WO1997010806A1 (en) 1997-03-27
US6524556B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
DE69630798D1 (de) Aerosolzusammensetzungen
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
AU662128B2 (en) New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments
BR9805993A (pt) Composição farmacêutica de aerosol.
MX9606501A (es) Composiciones antifungosas y curativas para heridas y metodos para preparar y utilizar las mismas.
CO5180575A1 (es) Composiciones antibacterianas orales de lupulona hidrogenda estable
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
JPS5659710A (en) Preventive and remedy for psoriasis
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
MY118301A (en) Local anesthetic for external use
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
DK0693926T3 (da) Ny farmaceutisk sammensætning til fremstilling af et stabilt pulver indeholdende en kombination af acetylsalicylsyre og metoclopramid som aktiv bestanddel.
NZ512194A (en) A pharmaceutical composition comprising cyclosporin in a lipid carrier
EP0968713A4 (de) Isosorbidnitrat enthaltentende pflaster
GR1002731B (el) Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE69809435D1 (de) Inhibitor- und konservierungsmittelzusammensetzung
EP0966958A4 (de) Aerosol-präparation
MY105086A (en) Liquid detergent composition.
ES456094A1 (es) Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo.
JPS5762220A (en) Embrocation for external use
KR910016314A (ko) 항생활성 성분의 치과용 국소지속성 투여조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0851753

Country of ref document: EP

REN Ceased due to non-payment of the annual fee